The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Sun., Oct. 26, 5:29 AM

Slide #14. PTC Therapeutics, Inc. Secondary Offering

Company: PTC Therapeutics, Inc. (NASDAQ:PTCT)
Date announced: 10/8/2014
Shares Offered: 3,000,000
Date of Pricing: 10/9/2014
Price Per Share: $36.25
Secondary Offering Details: PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it is commencing an underwritten public offering of 3,000,000 shares of its common stock pursuant to an automatically effective shelf registration statement that was previously filed with the Securities and Exchange Commission. All of the shares in the offering are to be sold by PTC. PTC intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 450,000 shares of common stock. The offering is subject to market conditions and other factors, and there can be no assurance as to whether or when the offering may be completed. - updated 10/9 - PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the pricing of an underwritten public offering of 3,000,000 shares of its common stock pursuant to an automatically effective shelf registration statement that was previously filed with the Securities and Exchange Commission at a public offering price of $36.25 per share, before underwriting discounts. All of the shares in the offering are to be sold by PTC. In addition, PTC has granted the underwriters an option for a period of 30 days to purchase up to an additional 450,000 shares of common stock at the public offering price, less the underwriting discount.

PTC Therapeutics is a biopharmaceutical company focused on the discovery and development of orally administered, small molecule drugs that target post-transcriptional control processes. Co.'s primary product candidate is ataluren for the treatment of patients with genetic disorders that arise from a type of genetic mutation known as a nonsense mutation. In addition to ataluren, Co. has a pipeline of product candidates that are in preclinical development. Co.'s preclinical and discovery programs are focused on the development of new treatments for multiple therapeutic areas, including neuromuscular disease, oncology and infectious disease.
Open the PTCT Page at The Online Investor »

Company Name:  PTC Therapeutics Inc
Website:  www.ptcbio.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding PTCT:  23
Total Market Value Held by ETFs:  $58.18M
Total Market Capitalization:  $1.11B
% of Market Cap. Held by ETFs:  5.23%
 

Open the PTCT Page at The Online Investor (in a new window) »

October 26, 2014    5:29 AM Eastern
Quotes delayed 20 minutes



Strong Buy (3.60 out of 4)
75th percentile
(ranked higher than approx. 75% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2014, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.